Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.42 |
| ▸ | GNAI3 | P08754 | 4/20 | 0.40 |
| ▸ | GNAI1 | P63096 | 4/20 | 0.40 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.35 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.35 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.35 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9668263 | 0.91 | NAAA (0.45) | GNAO1HRH3CXCR4NAAA | |
| SCHEMBL5488178 | 0.90 | HRH3 (0.45) | GNAO1HRH3CXCR4NAAA | |
| SCHEMBL7129008 | 0.89 | GNAO1 (0.58) | GNAO1HRH3CXCR4GNAI3GNAI1 | |
| SCHEMBL7126423 | 0.87 | GNAO1 (0.57) | GNAO1HRH3CXCR4GNAI3GNAI1 | |
| SCHEMBL9674013 | 0.86 | CXCR4 (0.49) | GNAO1HRH3CXCR4NAAA | |
| SCHEMBL7129884 | 0.85 | GNAO1 (0.58) | GNAO1HRH3CXCR4GNAI3GNAI1 | |
| SCHEMBL7462427 | 0.85 | CYP1A2 (0.43) | GNAO1HRH3CXCR4GNAI3GNAI1 | |
| SCHEMBL9673755 | 0.84 | CXCR4 (0.48) | HRH3CXCR4NAAA | |
| SCHEMBL9676455 | 0.84 | CXCR4 (0.48) | HRH3CXCR4NAAA | |
| SCHEMBL3395893 | 0.84 | CXCR4 (0.50) | GNAO1CXCR4GNAI3GNAI1SLC6A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2858970-A1 | PROCESS FOR PREPARING FORMIC ACID | BASF SE (DE) | 2015-04-15 | — | — | EP | claimed |
| WO-2013186156-A1 | PROCESS FOR PREPARING FORMIC ACID | BASF SE (DE) | 2013-12-19 | — | — | WO | claimed |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-07-16 | — | — | US | disclosed |
| US-7429597-B2 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2008-09-30 | — | — | US | disclosed |
| EP-1583757-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2005-10-12 | — | — | EP | disclosed |
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-09-09 | — | — | US | disclosed |
| WO-2004058743-A1 | NOVEL SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES AND USE THEREOF AS FACTOR XA INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176603-A1 | Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions | F11, F12, F2 | GNAO1 138/4885HRH3 963/4885CXCR4 1344/4885 |
| US-20090181958-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROBICYCLES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | F12, F11, F2 | GNAO1 153/4885HRH3 457/4885CXCR4 938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.